| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Current | Unavailable | Manufacturing | 27/09/2024 |
| salbutamol sulfate | Inhalation, conventional | 3 mg | Current | Unavailable | Manufacturing | 27/09/2024 |
| framycetin sulfate~dexamethasone~gramicidin | Ear Drops | 5 mg/mL~.5 mg/mL~.05 mg/mL | Current | Limited Availability | Manufacturing | 27/09/2024 |
| octreotide | Injection, solution | 100 microgram | Current | Limited Availability | Manufacturing | 27/09/2024 |
| octreotide | Injection, solution | 500 microgram | Current | Unavailable | Manufacturing | 27/09/2024 |
| octreotide | Injection, solution | 50 microgram | Current | Unavailable | Manufacturing | 27/09/2024 |
| buprenorphine hydrochloride | Injection, solution | 324 microgram/mL | Current | Unavailable | Manufacturing | 27/09/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| metronidazole | Tablet, uncoated | 400 mg | Resolved | Available | Manufacturing | 27/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| tranexamic acid | Injection, solution | 1000 mg | Anticipated | Available | Commercial Changes / Commercial viability | 27/09/2024 |
| fenofibrate | Tablet | 48 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Unavailable | Manufacturing | 27/09/2024 |
| tadalafil | Tablet | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 27/09/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Unavailable | Manufacturing | 27/09/2024 |
| phenytoin sodium | Capsule, hard | 100 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| gliclazide | Tablet, modified release | 30 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/09/2024 |
| modafinil | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 27/09/2024 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 27/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Anticipated | Available | Manufacturing | 27/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Anticipated | Available | Manufacturing | 27/09/2024 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 27/09/2024 |
| clonazepam | Tablet, uncoated | 2 mg | Current | Limited Availability | Manufacturing | 27/09/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 27/09/2024 |
| morphine sulfate pentahydrate | Capsule, modified release | 120 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 27/09/2024 |
| morphine sulfate pentahydrate | Capsule, modified release | 90 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 27/09/2024 |
| morphine sulfate pentahydrate | Capsule, modified release | 60 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 27/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Resolved | Available | Manufacturing | 27/09/2024 |
| primidone | Tablet, uncoated | 250 mg | Current | Limited Availability | Manufacturing | 26/09/2024 |
| ramipril | Capsule, hard | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| propofol | Injection, emulsion | 500 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| oxytocin | Injection, solution | 10 IU | Anticipated | Available | Manufacturing | 26/09/2024 |
| temozolomide | Capsule, hard | 100 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 26/09/2024 |
| lurasidone hydrochloride | Tablet, film coated | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 10.9 mg~10 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| epirubicin hydrochloride | Injection, concentrated | 200 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Unavailable | Unexpected increase in consumer demand | 26/09/2024 |
| lidocaine hydrochloride | Injection, solution | 400 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Limited Availability | Manufacturing | 26/09/2024 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| bortezomib | Injection, solution | 3.5 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| bisoprolol fumarate | Tablet, film coated | 2.5 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 26/09/2024 |
| bisoprolol fumarate | Tablet, film coated | 5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| bisoprolol fumarate | Tablet, film coated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/09/2024 |
| pamidronate disodium | Injection, concentrated | 3 mg | Current | Unavailable | Manufacturing | 26/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 25/09/2024 |
| Rabies virus | Injection, powder for | 2.5 IU | Current | Emergency Supply Only | Manufacturing | 25/09/2024 |
| latanoprost~timolol maleate | Eye Drops, solution | .05 mg/mL~6.83 mg/mL | Anticipated | Available | Manufacturing | 25/09/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 25/09/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 25/09/2024 |
| gefitinib | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 25/09/2024 |
| lurasidone hydrochloride | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 25/09/2024 |
| Rabies virus | Powder | 3.25 IU | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 25/09/2024 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 25/09/2024 |
| propranolol hydrochloride | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 24/09/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Current | Limited Availability | Manufacturing | 24/09/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 24/09/2024 |
| midazolam | Injection, solution | 5 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/09/2024 |
| midazolam | Injection, solution | 1 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Unavailable | Manufacturing | 24/09/2024 |
| buprenorphine | Drug delivery system, transdermal | 40 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 24/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 24/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 24/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 24/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 24/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 24/09/2024 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Resolved | Available | Manufacturing | 24/09/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 24/09/2024 |
| heparin sodium | Injection, solution | 10 IU/mL | Current | Limited Availability | Manufacturing | 24/09/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg | Current | Unavailable | Manufacturing | 24/09/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 4.8 mg~.512 mg | Current | Limited Availability | Manufacturing | 24/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/09/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 23/09/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 23/09/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 483 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 23/09/2024 |
| esomeprazole magnesium dihydrate | Tablet, enteric coated | 21.75 mg | Resolved | Available | Manufacturing | 23/09/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 23/09/2024 |
| milrinone | Injection, concentrated | 10 mg | Current | Limited Availability | Manufacturing | 23/09/2024 |
| hydromorphone hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/09/2024 |
| hydromorphone hydrochloride | Injection, solution | 10 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/09/2024 |
| hydromorphone hydrochloride | Injection, concentrated | 50 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/09/2024 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Anticipated | Available | Manufacturing | 23/09/2024 |
| levothyroxine sodium | Tablet, uncoated | .075 mg | Anticipated | Available | Manufacturing | 23/09/2024 |
| erythromycin ethyl succinate | Oral Liquid, powder for | 468 mg | Current | Limited Availability | Unexpected increase in consumer demand | 23/09/2024 |
| desmopressin acetate | Spray, solution | .1 mg/mL | Current | Unavailable | Product recall | 23/09/2024 |
| rizatriptan benzoate | Wafer | 14.53 mg | Current | Limited Availability | Manufacturing | 23/09/2024 |
| midazolam | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 23/09/2024 |
| oxycodone hydrochloride | Capsule, hard | 5 mg | Anticipated | Available | Manufacturing | 23/09/2024 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/09/2024 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/09/2024 |
2024年9月30日